Key result
Female sex was not associated with a difference in 30-day and late mortality compared to male sex among patients with primary malignant cardiac tumors (p = 0.71).
Why the study?
Despite the clinical importance of sex in cancer progression and survival, it remains one of the least studied factors, prompting this examination of sex differences in primary malignant cardiac tumors.
Are there sex differences in overall survival among patients with primary malignant cardiac tumors?
Cohort (n=736)
Yes
Are there sex differences in overall survival among patients with primary malignant cardiac tumors?
p-value: p=.71
In a national cohort of primary malignant cardiac tumors, overall survival is poor and driven by age, comorbidity, histology, and stage, with no significant differences in mortality between sexes.
No takes yet. Share an insight, caveat, or question.
No survival difference by sex in PMCTs; leaves open whether sex influences tumor biology or treatment response.
Rahouma et al. (2022) conducted a cohort in Primary malignant cardiac tumors (n=736). Female sex vs. Male sex was evaluated on 30-day and late mortality (p=.71). Female sex was not associated with a difference in 30-day and late mortality compared to male sex among patients with primary malignant cardiac tumors (p = 0.71).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: